Alaska Tuberculosis Program Manual - Epidemiology - State of Alaska
Alaska Tuberculosis Program Manual - Epidemiology - State of Alaska Alaska Tuberculosis Program Manual - Epidemiology - State of Alaska
thousands to millions of copies of a particular DNA sequence. TB PCR may allow rapid detection of M. tuberculosis Complex DNA present in patient samples. potential ongoing transmission: A risk classification for TB screening, including testing for M. tuberculosis infection when evidence of ongoing transmission of M. tuberculosis is apparent in the setting. Testing might need to be performed every 8–10 weeks until lapses in infection controls have been corrected and no further evidence of ongoing transmission is apparent. Use potential ongoing transmission as a temporary risk classification only. After corrective steps are taken, reclassify the setting as medium risk. Maintaining the classification of medium risk for at least 1 year is recommended. powered air-purifying respirator (PAPR): A respirator equipped with a tight-fitting facepiece (rubber facepiece) or loose-fitting facepiece (hood or helmet), breathing tube, air-purifying filter, cartridge or canister, and a fan. Air is drawn through the air-purifying element and pushed through the breathing tube and into the facepiece, hood, or helmet by the fan. Loose-fitting PAPRs (e.g., hoods or helmets) might be useful for persons with facial hair because they do not require a tight seal with the face. prevalence: The proportion of persons in a population who have a disease at a specific time. pulmonary TB: TB disease that occurs in the lung parenchyma, usually producing a cough that lasts 2 to 3 weeks. purified protein derivative (PPD) tuberculin: A material used in diagnostic tests for M. tuberculosis infection. In the United States, PPD solution (5 tuberculin units per 0.1 mL) is approved for administration as an intradermal injection as a diagnostic aid for M. tuberculosis infection (latent infection or TB disease). QuantiFERON ® -TB Gold in-tube (QFT-GIT), QuantiFERON ® -TB test (QFT), and QuantiFERON ® -TB Gold test (QFT-G): Types of blood assays for M. tuberculosis that are in vitro cytokine assays that detects cell-mediated immune response to M. tuberculosis in heparinized whole blood from venipuncture. This test requires only a single patient encounter, and the result can be ready within 1 day. In 2005, QFT was replaced by QFT-G, and in 2007 the QFT was approved by the FDA. The QFT-G and QFT have greater specificity than the original QFT. QFT-G and QFT appear to be capable of distinguishing between the sensitization caused by M. tuberculosis infection and that caused by bacille Calmette-Guérin vaccination. The QFT test has an advantage over the QFT-G test in that the QFT allows longer time (3 days) between the blood specimen collection and its arrival at a qualified laboratory. The blood specimen for the QFT-G test must arrive at the laboratory within 12 hours of collection. A L A S K A T U B E R C U L O S I S P R O G R A M M A N U A L Glossary 20. 11 Revised November 2012
adiography: The diagnostic imaging techniques (including plain-film chest radiographs and computerized tomography) that rely on degrees of X-radiation transmission related to differences in tissue densities. reinfection: A second infection that follows from a previous infection by the same causative agent. Frequently used when referring to an episode of TB disease resulting from a subsequent infection with M. tuberculosis and a different genotype. resistance: The ability of certain strains of mycobacteria, including M. tuberculosis, to grow and multiply in the presence of certain drugs that ordinarily kill or suppress them. Such strains are referred to as drug-resistant strains and cause drugresistant TB disease. See also multidrug-resistant TB. respirator: A Centers for Disease Control and Prevention (CDC)/National Institute for Occupational Safety and Health (NIOSH)-approved device worn to prevent inhalation of airborne contaminants. respiratory hygiene and cough etiquette: Procedures by which patients with suspected or confirmed infectious TB disease can minimize the spread of infectious droplet nuclei by decreasing the number of infectious particles that are released into the environment. Patients with a cough should be instructed to turn their heads away from persons and to cover their mouth and nose with their hands or preferably a cloth or tissue when coughing or sneezing. respiratory protection: The third level in the hierarchy of TB infection control measures (after administrative and environmental controls) is the use of respiratory protective equipment in situations in which the administrative and environmental controls do not eliminate the risk that exposures can still occur (e.g., airborne infection isolation rooms and rooms where cough-inducing or aerosol-generating procedures are performed). risk assessment (TB): An initial and ongoing evaluation of the risk for transmission of M. tuberculosis in a particular healthcare setting. To perform a risk assessment, the following factors should be considered: the community rate of TB, number of TB patients encountered in the setting, and the speed with which patients with TB disease are suspected, isolated, and evaluated. The TB risk assessment determines the types of administrative and environmental controls and respiratory protection needed for a setting. screening (TB): An administrative control measure in which evaluation for latent TB infection and TB disease are performed through initial and serial screening of healthcare workers, as indicated. Evaluation might comprise tuberculin skin test, blood assay for M. tuberculosis, chest radiograph, and symptom screening. See also symptom screen. A L A S K A T U B E R C U L O S I S P R O G R A M M A N U A L Glossary 20. 12 Revised November 2012
- Page 419 and 420: ! ?"#51)09/02!H0/.!9:(78;7)37028!/'
- Page 421 and 422: Latent Tuberculosis Infection (LTBI
- Page 423 and 424: Alaska Tuberculosis Program 9210 Va
- Page 425 and 426: Instructions for Collecting Sputum
- Page 427 and 428: TB Case Management Information Requ
- Page 429 and 430: Table 1: First-line anti-tuberculos
- Page 431 and 432: Return the fax to the Drug Room (90
- Page 433 and 434: Stock Orders: A small supply of
- Page 435 and 436: TB/LTBI Medication Return Form Reas
- Page 437 and 438: TB/LTBI Stock Medication Request FA
- Page 439 and 440: TB Medication Dose Monitoring Regim
- Page 441 and 442: TB Medication Dose Monitoring Regim
- Page 443 and 444: ALASKA DEPARTMENT OF HEALTH AND SOC
- Page 445: Tuberculosis Discharge Planning Che
- Page 448 and 449: PART 2: 8. Have you ever been told
- Page 450 and 451: Tuberculosis Treatment Contract Dep
- Page 452 and 453: Statutes and Regulations Contents I
- Page 454 and 455: Regulations Infection Control 7 AAC
- Page 456 and 457: place of work is remote from patien
- Page 458 and 459: (2) the child or a person acting on
- Page 460 and 461: Glossary acid-fast bacilli (AFB): M
- Page 462 and 463: eaction size on a later test, which
- Page 464 and 465: disseminated TB: See miliary TB. dr
- Page 466 and 467: immunocompromised and immunosuppres
- Page 468 and 469: include medical history and TB symp
- Page 472 and 473: secondary (TB) case: A new case of
- Page 474: eproducing TB organisms from respir
adiography: The diagnostic imaging techniques (including plain-film chest radiographs<br />
and computerized tomography) that rely on degrees <strong>of</strong> X-radiation transmission<br />
related to differences in tissue densities.<br />
reinfection: A second infection that follows from a previous infection by the same<br />
causative agent. Frequently used when referring to an episode <strong>of</strong> TB disease<br />
resulting from a subsequent infection with M. tuberculosis and a different<br />
genotype.<br />
resistance: The ability <strong>of</strong> certain strains <strong>of</strong> mycobacteria, including M. tuberculosis, to<br />
grow and multiply in the presence <strong>of</strong> certain drugs that ordinarily kill or suppress<br />
them. Such strains are referred to as drug-resistant strains and cause drugresistant<br />
TB disease. See also multidrug-resistant TB.<br />
respirator: A Centers for Disease Control and Prevention (CDC)/National Institute for<br />
Occupational Safety and Health (NIOSH)-approved device worn to prevent<br />
inhalation <strong>of</strong> airborne contaminants.<br />
respiratory hygiene and cough etiquette: Procedures by which patients with<br />
suspected or confirmed infectious TB disease can minimize the spread <strong>of</strong><br />
infectious droplet nuclei by decreasing the number <strong>of</strong> infectious particles that are<br />
released into the environment. Patients with a cough should be instructed to turn<br />
their heads away from persons and to cover their mouth and nose with their<br />
hands or preferably a cloth or tissue when coughing or sneezing.<br />
respiratory protection: The third level in the hierarchy <strong>of</strong> TB infection control measures<br />
(after administrative and environmental controls) is the use <strong>of</strong> respiratory<br />
protective equipment in situations in which the administrative and environmental<br />
controls do not eliminate the risk that exposures can still occur (e.g., airborne<br />
infection isolation rooms and rooms where cough-inducing or aerosol-generating<br />
procedures are performed).<br />
risk assessment (TB): An initial and ongoing evaluation <strong>of</strong> the risk for transmission <strong>of</strong><br />
M. tuberculosis in a particular healthcare setting. To perform a risk assessment,<br />
the following factors should be considered: the community rate <strong>of</strong> TB, number <strong>of</strong><br />
TB patients encountered in the setting, and the speed with which patients with<br />
TB disease are suspected, isolated, and evaluated. The TB risk assessment<br />
determines the types <strong>of</strong> administrative and environmental controls and<br />
respiratory protection needed for a setting.<br />
screening (TB): An administrative control measure in which evaluation for latent TB<br />
infection and TB disease are performed through initial and serial screening <strong>of</strong><br />
healthcare workers, as indicated. Evaluation might comprise tuberculin skin test,<br />
blood assay for M. tuberculosis, chest radiograph, and symptom screening. See<br />
also symptom screen.<br />
A L A S K A T U B E R C U L O S I S P R O G R A M M A N U A L Glossary 20. 12<br />
Revised November 2012